

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Crizotinib for previously untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer**

**Batch 44**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was noted that testing could be restricted to patients with a diagnosis of adenocarcinoma.

It was also noted that there could be inequitable access if regional variations in ALK testing exist.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Neither of these issues raised relate to protected characteristics, as defined by the Equalities Act, and therefore were not considered equality issues.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change to the draft scope has been agreed to highlight potential equality issues.

4. Have any additional stakeholders related to potential equality issues

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of Crizotinib for previously untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Issue date: November 2015

been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues have been identified.

**Approved by Associate Director (name):** Melinda Goodall

**Date:** 10/11/2015